FDAnews Drug Daily Bulletin

GENELABS ANNOUNCES FORECAST OF MID-YEAR CASH LEVEL AND NOTIFICATION FROM NASDAQ

June 12, 2006
A A

Genelabs Technologies, Inc. announced today that, after its receipt of $12.5 million in up-front payments under its recently announced agreement with Novartis, Genelabs expects its June 30, 2006 cash and cash equivalents to be approximately $15 million. The mid-year cash level anticipated by the company accounts for costs related to closing the transaction and anticipated second quarter operating expenses. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-09-2006/0004377619&EDATE=)